Crossmark

Guillain-Barre syndrome observed with adoptive transfer of lymphocytes genetically engineered with an NY-ESO-1 reactive T-cell receptor

Crossref DOI link: https://doi.org/10.1186/s40425-019-0759-x

Published Online: 2019-11-08

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Joseph, Jocelyn http://orcid.org/0000-0002-5618-0819
Nathenson, Michael J.

Trinh, Van Anh

Malik, Karan

Nowell, Erica

Carter, Kristen

Weathers, Shiao-Pei

Demetri, George D.

Araujo, Dejka

Conley, Anthony P.
License Information

Text and Data Mining valid from 2019-11-08
More Information

Article History

Received: 3 May 2019

Accepted: 26 September 2019

First Online: 8 November 2019

Ethics approval and consent to participate

: The present study was conducted in accordance with all accepted standard for the ethical conduct of human subject’s research. Written informed consent was obtained from the patient at the time of enrollment. Approval was obtained from GSK and Adaptimmune for publication of this manuscript.

: Consent for publication has been obtained for both patient cases.

: SPW reports research support from Genentech and Mundipharma. AC receives research support from Ignyta, Iovance, Nektar, and Novartis. All other authors report no disclosures.